Floatz logo

(2R,6R)-HYDROXYNORKETAMINE

Neurotransmitter Agents

National Institute of Mental Health (NIMH)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Neurotransmitter Agents cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
Vts-K
Theresa Jacob, PhD, MPH
Phase 4BB
MIDAZOLAM
Theresa Jacob, PhD, MPH
Phase 3B
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Theresa Jacob, PhD, MPH
Phase 3B
ly03010
Luye Pharma Group Ltd.
Phase 1CCC
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 1CC
LIDOCAINE
Aretaieion University Hospital
N/AD

Same molecule, other indications

(2R,6R)-HYDROXYNORKETAMINE is also rated in:

depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
KetamineDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →